WEEKLY IMPORTANT NEWS FROM MEDSCAPE AND OTHER SOURCES
Κυριακή, 28 Φεβρουαρίου 2016
USE OF OVARIAN SUPPRESSION IN BREAST CANCER
As reported in the Journal of Clinical Oncology by Burstein et al, ASCO has released a clinical practice guideline update on ovarian suppression as part of the extant guideline on adjuvant endocrine therapy in hormone receptor–positive breast cancer. The update is based on an update panel review of recent randomized clinical trial data on ovarian suppression. The panel recommendations are reproduced here.
The guideline update addressed the following questions with regard to premenopausal women with stage I to III hormone receptor–positive breast cancer:
(1) Should premenopausal women with estrogen receptor–positive tumors receive adjuvant ovarian suppression in addition to standard adjuvant therapy, and, if so, in which subsets of patients?
(2) If ovarian suppression is recommended, should ovarian suppression be administered in combination with tamoxifen or an aromatase inhibitor?
1.1—The panel recommends that higher-risk patients should receive ovarian suppression in addition to adjuvant endocrine therapy, whereas lower-risk patients should not.
Qualifying Statement: The panel notes that two prospective studies did not show an overall clinical benefit for the addition of ovarian suppression to tamoxifen in premenopausal, estrogen receptor–positive breast cancer. However, in a large subset of women with higher-risk cancers, nearly all of whom received chemotherapy but remained premenopausal, ovarian suppression added to tamoxifen reduced the risk of breast cancer recurrence. Because of the design of the clinical trials, there are few definitive criteria by which to define risk.
1.2—Women with stage II or stage III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression in addition to endocrine therapy.
1.3—Women with stage I or II breast cancers at higher risk of recurrence, who might consider chemotherapy, may also be offered ovarian suppression in addition to endocrine therapy.
1.4—Women with stage I breast cancers not warranting chemotherapy should receive endocrine therapy but not receive ovarian suppression.
1.5—Women with node-negative cancers 1 cm or less (T1a, T1b) should receive endocrine therapy but not ovarian suppression.
[Benefits: increasing disease-free survival, freedom from breast cancer, and freedom from distance recurrence. Harms: worse menopausal symptoms and sexual functioning, including hot flashes, sweating, weight gain, vaginal dryness, and decreased libido] [Evidence quality = intermediate. Recommendation type = evidence based and consensus. Recommendation strength = moderate]
The standard duration of ovarian suppression in the included trials was 5 years. With no comparative data available on alternative durations, the panel supports ovarian suppression for 5 years.
To date, there is no adequate evidence for assessing the benefit of adjuvant ovarian suppression in women at sufficient risk to warrant chemotherapy compared with 10 years of tamoxifen.
There is no current role for ovarian suppression as adjuvant therapy in estrogen receptor–negative breast cancers.
There are substantial adverse effects to ovarian suppression. Clinicians and patients should consider the trade-offs of adverse effects when choosing ovarian suppression.
The long-term effects of ovarian suppression on breast cancer risk and survival are not yet established.
2—Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor.
[Benefits: increasing disease-free survival, freedom from breast cancer, and freedom from distance recurrence. Harms: worse menopausal symptoms and sexual functioning, including hot flashes, sweating, weight gain, vaginal dryness, and decreased libido; osteopenia/osteoporosis] [Evidence quality = high. Recommendation type = evidence based. Recommendation strength = strong]
Tamoxifen and aromatase inhibitor therapy differ in their adverse-effect profiles, which may affect patient preferences.
Clinicians should be alert to the possibility of incomplete ovarian suppression with gonadotropin-releasing hormone agonist therapy and should evaluate patients in whom there is concern for residual ovarian function.
Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, is the corresponding author of the Journal of Clinical Oncology article, c/o the American Society of Clinical Oncology.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.